In esophageal adenocarcinoma, AXL has been found to block apoptosis and foster drug resistance by suppressing c-ABL/p73 signaling in response to cisplatin.170 In addition, increased levels of AXL have been shown to stimulate ERK/mTOR signaling, triggering simultaneous DNA damage and repair signals. Here, AXL is linked to esophageal adenocarcinoma.